Swiss families hit by Dafalgan syrup shortage face unexpected costs

A widespread shortage of Dafalgan syrup has left Swiss families struggling to find the common children's medication. Many are now paying the full price for alternatives, even with a prescription, as pharmacies run out of stock.

The problem began in late 2023 when manufacturer UPSA planned to update the syrup's packaging. However, Swissmedic, the country's drug regulator, initially approved the change only for Dafalgan Dolo—the non-reimbursable version. This delay disrupted production of the prescription syrup, leaving shelves empty for months.

Production of the newly packaged syrup is set to restart in late February. The first shipments should reach pharmacies in March, with supplies gradually returning throughout spring. Until then, families must either pay out of pocket for Dafalgan Dolo—which is chemically identical but not covered by insurance—or seek other options.

The shortage has caused frustration, as prescriptions no longer guarantee the usual reimbursement. Many parents now face unexpected costs for a medication once widely available at a lower price.

UPSA is working to resolve the issue by resuming production of the reimbursable syrup. Once supplies return, families will no longer need to cover the full cost. The gradual restocking process, however, means some may still face delays in the coming weeks.